Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Alpha2-agonists in development at R.W. Johnson for use as analgesics

March 25, 1999

Intranasal dosing with BMS-181885 appears feasible, according to preliminary human data

March 25, 1999

LY-334370: pharmacokinetics and safety during and outside a migraine attack

March 25, 1999

Kampo medicine demonstrates anxiolytic efficacy in mice

March 25, 1999

Lack of efficacy for lanepitant in neuropathic pain

March 25, 1999

GTS-21 and donepezil exert synergistic cognition-enhancing effects in rats

March 25, 1999

Fujisawa presents COX-2 inhibitor with potent, morphine-like analgesic effects

March 25, 1999

R.W. Johnson identifies mixed adrenergic agent with analgesic activity

March 25, 1999

N-type Ca2+ blockers from Warner-Lambert for neurological disorders

March 25, 1999

Highlights from ACS: potent and selective alpha2-blocker presented by Pierre Fabre

March 24, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...